Immuno-Oncology Market: North America to Retain Dominance by 2025-End


Increasing prevalence of carcinogenic disorders has revved up adoption of the immuno-oncology therapy globally. Moreover, growing preference for treatment procedures that have relatively low toxicity is further expected to impact the global market growth of immune-oncology positively. Persistence Market Research has published a report recently, which states that the global immune-oncology market is expected to register 16.5% CAGR during the forecast period, 2016-2025.

The global immune-oncology market is expected to witness significant growth bound to several micro-economic and macro-economic factors. As the immunotherapy drugs have been clinically approved for the treatment of the carcinogenic disorder, adoption of the immunotherapy treatment is expected to rev up. Clinical approval of the immunotherapy drugs is expected to rev up investments in the global market. Moreover, increasing investment in the immunotherapy drugs is further expected to underscore lucrative growth opportunities for the market globally. Initiatives and collaborative efforts taken for disorders that have challenging treatment is further expected to contribute towards growth of the global market.

On the other hand, several factors are expected to inhibit growth of the global market of immune-oncology during the forecast period. Increasing development cost, lack of technical skills, and expensive prices of medicines is expected to pose significant challenges in the global market. These factors are likely to inhibit the global market growth of immune-oncology throughout the forecast period.

Immune checkpoint inhibitor therapy is increasingly used for the treatment of carcinogenic disorders globally. This treatment helps in suppressing the immune responses and fighting proteins that help the tumor to grow. In terms of sales revenue, the immune checkpoint inhibitor drugs is expected to record nearly US$ 7,321.7 Mn by the end of 2017.

The immune checkpoint inhibitor drugs such as Tecentriq, Opidov and Keytruda, and Yervoy have been approved by the U.S. FDA, which has led to an upsurge in demand for these drugs globally. Moreover, increasing investment made by the market players in the biopharmaceutical for developing a robust pipeline is further expected to impact growth of the global market. The immune system modulator is likely to remain the second highest preferred treatment and will represent an incremental opportunity of nearly US$ 659.9 Mn by the end of 2025. Interleukins and interferons are expected to represent the major drugs approved by the U.S. FDA in this category.

On the basis of therapeutic area, increasing demand for immuno-oncology therapy for diseases such as melanoma will remain a leading segment during the forecast period. Hospitals as compared to the other end users is further expected to represent the largest revenue share in the global market, accounting for nearly US$ 5,557.1 Mn by 2017 and beyond. This is mainly attributed to increasing presence of leading drug manufacturers in the U.S.

North America as compared to the other regions is expected to account for 67.1% revenue share in 2016. The immune-oncology market in this region is expected to retain dominance in the global market, recording a robust 17.1% CAGR throughout the forecast period. Attributed to increasing presence of leading drug manufacturers, the U.S. is expected to remain dominant in the North America market during the forecast period.

Leading players in the global immuno-oncology market are AstraZeneca Plc, Dendreon Corporation, Amgen, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Pfizer, Inc., F.Hoffmann-La Roche, Sanofi, and Novartis AG.

Request and Download Sample Report

Leave a Reply